Home › Funds › Legato Capital Management LLC › ADPT

Legato Capital Management LLC position in ADPT

ADAPTIVE BIOTECHNOLOGIES COR · Health Care

Legato Capital Management LLC reported holding 186,910 shares of ADPT (ADAPTIVE BIOTECHNOLOGIES COR) in its Q3 2026 13F filing — a position valued at US$5.4M, representing 0.52% of its reported portfolio and ranking #24 among its reported holdings. Legato Capital Management LLC has disclosed ADPT holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)186.91K sh
Reported value held$5.40M
Portfolio Weight0.52%
First reportedQ3 2023
Last changeReduce
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How Legato Capital Management LLC's ADPT position evolved

Legato Capital Management LLC first disclosed a stake in ADPT in Q3 2023 at 97,494 shares (US$531K). The position peaked in Q2 2026 at 273,441 shares, worth US$5.9M. Across 13 filings, Legato Capital Management LLC increased the stake 5 time(s), trimmed it 4 time(s) and left it unchanged 3 time(s). The most recent filing (Q3 2026) shows 186,910 shares valued at US$5.4M — a reduction of -86,531 shares quarter over quarter.. Notable position changes include a 64% increase in Q2 2024 (shares rose 41% over the following quarter), a 36% trim in Q1 2026 (shares rose 55% over the following quarter), a 79% increase in Q2 2026 (shares rose 35% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 97.49K $531.34K New
Q4 2023 128.05K $627.47K Add
Q1 2024 128.05K $411.05K Hold
Q2 2024 209.70K $759.12K Add
Q3 2024 241.36K $1.24M Add
Q4 2024 184.67K $1.11M Reduce
Q1 2025 182.45K $1.36M Reduce
Q2 2025 182.03K $2.12M Hold
Q3 2025 238.01K $3.56M Add
Q4 2025 238.61K $3.87M Hold
Q1 2026 152.34K $2.11M Reduce
Q2 2026 273.44K $5.87M Add
Q3 2026 186.91K $5.40M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About ADPT and 13F data

ADPT (ADAPTIVE BIOTECHNOLOGIES COR) is a Health Care company. 58 other funds we track also report a position in ADPT — the largest reported positions include Viking Global Investors (US$643.4M), VIKING GLOBAL INVESTORS LP (US$643.4M), Aristotle Atlantic Partners, LLC (US$39.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding ADPT

All ADPT fund holders →

FAQ

How long has Legato Capital Management LLC held ADPT?

Legato Capital Management LLC has disclosed ADPT holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is Legato Capital Management LLC's current position in ADPT?

As of Q3 2026, Legato Capital Management LLC holds 186.91K shares of ADPT (ADAPTIVE BIOTECHNOLOGIES COR), valued at $5.40M, representing 0.52% of its reported portfolio and ranking #24.

Has Legato Capital Management LLC been buying or selling ADPT?

In the latest 13F filing (Q3 2026), Legato Capital Management LLC reduced its position in ADPT. The position peaked in Q2 2026 at 273.44K shares.

Which other funds hold ADPT?

Other major institutional holders of ADPT include Viking Global Investors, VIKING GLOBAL INVESTORS LP, Aristotle Atlantic Partners, LLC, among 58 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.